Figure 3
From: Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
(A) Neutralizing antibody results measured by live virus microneutralization assay (Micro-VNT50) against SARS-CoV-2 wild type virus. Seroconversion defines as Micro-VNT50 titer ≥ 10. (B) SARS-Cov-2-specific serum neutralizing antibody titres measured by pseudovirus neutralization test (psVNT50). Seroconversion defines as psVNT-50 titer ≥ 10. (C) SARS-CoV2 receptor binding domain (RBD) antibody titres measured by ELISA. Seroconversion defines as anti-RBD-IgG ≥ 50 U/mL.
